var data={"title":"Sclerosing mesenteritis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Sclerosing mesenteritis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/contributors\" class=\"contributor contributor_credentials\">Lawrence S Friedman, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/contributors\" class=\"contributor contributor_credentials\">Darrell Pardi, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/contributors\" class=\"contributor contributor_credentials\">J Thomas Lamont, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/contributors\" class=\"contributor contributor_credentials\">Shilpa Grover, MD, MPH, AGAF</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 17, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sclerosing mesenteritis is a rare, non-neoplastic inflammatory and fibrotic disease that affects the mesentery. Sclerosing mesenteritis can affect the integrity of the gastrointestinal lumen and mesenteric vessels by a mass effect. Sclerosing mesenteritis can result in a variety of gastrointestinal and systemic manifestations, including abdominal pain, nausea and vomiting, diarrhea, weight loss, and fever [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/1-4\" class=\"abstract_t\">1-4</a>]. This topic will review the epidemiology, etiology, clinical manifestations, diagnosis, and management of sclerosing mesenteritis. </p><p class=\"headingAnchor\" id=\"H4212209001\"><span class=\"h1\">TERMINOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sclerosing mesenteritis is often used as an umbrella term for a spectrum of idiopathic primary inflammatory and fibrotic processes that affect the mesentery [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/5,6\" class=\"abstract_t\">5,6</a>]. Several terms have been used to describe this process based on the degree of inflammation and fibrosis, these include mesenteric lipodystrophy (with a predominance of fat necrosis) and sclerosing mesenteritis or mesenteric fibrosis (with a predominance of fibrosis) (<a href=\"image.htm?imageKey=GAST%2F64321\" class=\"graphic graphic_table graphicRef64321 \">table 1</a>). Patients usually have a range of pathologic findings, with varying components of inflammation, fibrosis, and fat necrosis, although usually one feature predominates at a given time. Histologic progression has only rarely been documented [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/7\" class=\"abstract_t\">7</a>]. It is quite likely that these features represent different points in the natural history of the underlying process, with adipocyte necrosis (mesenteric lipodystrophy) evolving into a chronic inflammatory state (mesenteric panniculitis), and finally to fibrosis (sclerosing mesenteritis). </p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sclerosing mesenteritis appears to be rare, and a significant proportion of patients are asymptomatic. In one autopsy series, the prevalence of sclerosing mesenteritis was one percent [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/8\" class=\"abstract_t\">8</a>]. In a prospective evaluation of over 7000 consecutive abdominal computed tomography examinations, the prevalence of sclerosing mesenteritis was 0.6 percent [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/9\" class=\"abstract_t\">9</a>]. Most patients in this study were Caucasian. Although sclerosing mesenteritis has been reported in persons as young as three years of age, it is diagnosed most commonly in the fifth to seventh decades of life, with a median age of 65 years [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/10,11\" class=\"abstract_t\">10,11</a>]. The low prevalence in childhood and adolescence may be attributable to a smaller amount of mesenteric fat [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/12\" class=\"abstract_t\">12</a>]. While most studies have found that the prevalence of sclerosing mesenteritis is higher in men, this has not been consistently demonstrated [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/6,9-11\" class=\"abstract_t\">6,9-11</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">ETIOLOGY AND PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathogenesis of sclerosing mesenteritis remain unclear, although several mechanisms have been postulated. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Abdominal</strong> <strong>surgery</strong> <strong>or</strong> <strong>abdominal</strong> <strong>trauma </strong>&ndash; It is hypothesized that sclerosing mesenteritis results in genetically predisposed individuals who have abnormal responses to healing and repair of connective tissue in response to trauma [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/6,13\" class=\"abstract_t\">6,13</a>]. In a systematic review of the published literature, previous abdominal surgery or abdominal trauma was described in almost 30 percent of patients [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/11\" class=\"abstract_t\">11</a>]. In one series of 92 patients with sclerosing mesenteritis, 38 patients (41 percent) had prior abdominal surgery, including cholecystectomy, appendectomy, hysterectomy, and colectomy [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/10\" class=\"abstract_t\">10</a>]. Sclerosing mesenteritis has been reported in association with both acute abdominal injury and chronic repetitive trauma (eg, pneumatic jackhammer) and inflammation (eg, occult ileal perforation) [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/14,15\" class=\"abstract_t\">14,15</a>]. The use of powdered surgical gloves has also been implicated in the development of abdominal fibrosis as a precursor to sclerosing mesenteritis [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/10\" class=\"abstract_t\">10</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Autoimmunity</strong> &ndash; Sclerosing mesenteritis has been reported in association with a number of immune-mediated conditions, including Riedel thyroiditis, primary sclerosing cholangitis, retroperitoneal fibrosis, and orbital pseudotumor [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/11,16\" class=\"abstract_t\">11,16</a>]. In addition, it has rarely been found as part of the initial presentation with autoimmune hemolytic anemia, minimal change nephropathy, systemic lupus erythematosus, relapsing polychondritis, multifocal fibrosclerosis, limited systemic sclerosis, and celiac-associated T-cell lymphoma [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/10,17-23\" class=\"abstract_t\">10,17-23</a>]. A possible autoimmune etiology is also supported by a clinical response to immunomodulatory medications including glucocorticoids, <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>, and <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/24-28\" class=\"abstract_t\">24-28</a>]. (See <a href=\"#H16\" class=\"local\">'Approach to management'</a> below.)</p><p/><p class=\"bulletIndent1\">One series described an association with elevated serum IgG4 <span class=\"nowrap\">and/or</span> autoimmune pancreatitis in some patients, suggesting a possible role for IgG4-related immunopathologic processes in the development of sclerosing mesenteritis [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/10\" class=\"abstract_t\">10</a>]. However, in the author&rsquo;s experience, underlying IgG4 disease, whether measured by serum levels of tissue staining, appears to be rare [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/29\" class=\"abstract_t\">29</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Paraneoplastic</strong> <strong>syndrome</strong> &ndash; Among patients with sclerosing mesenteritis, an underlying malignancy has been reported from 1 to 75 percent [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/1,2,6,9,11,30\" class=\"abstract_t\">1,2,6,9,11,30</a>]. Non-Hodgkin lymphoma is the most commonly associated malignancy, however, others include breast cancer, carcinoid, melanoma, squamous carcinoma and adenocarcinoma of the lung, renal carcinoma, multiple myeloma, hepatocellular carcinoma, prostate adenocarcinoma, ovarian carcinoma, endometrial carcinoma, cervical carcinoma, angiosarcoma, and gastrointestinal adenocarcinomas [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/2,9,30,31\" class=\"abstract_t\">2,9,30,31</a>]. While it has been hypothesized that sclerosing mesenteritis represents a nonspecific response to an underlying malignancy and is a paraneoplastic syndrome, other studies have not demonstrated an association [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/32\" class=\"abstract_t\">32</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Ischemia</strong> <strong>and</strong> <strong>infection</strong> &ndash; A process mimicking sclerosing mesenteritis has been replicated in laboratory animals by a variety of methods, such as interference with the mesenteric vascular supply and injection of bacteria and bacterial toxins into the mesentery. A possible infectious etiology is consistent with case reports of sclerosing mesenteritis in patients with a history of typhoid fever, dysentery, tuberculosis, syphilis, malaria, influenza, and rheumatic fever [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/33\" class=\"abstract_t\">33</a>].</p><p/><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">CLINICAL PRESENTATION</span></p><p class=\"headingAnchor\" id=\"H2935853926\"><span class=\"h2\">Clinical features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately 10 to 15 percent of patients with sclerosing mesenteritis are asymptomatic or have minimal symptoms [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/9,34\" class=\"abstract_t\">9,34</a>]. </p><p>The most common presenting features are abdominal pain (30 to 70 percent), systemic symptoms including fever, malaise and weight loss (20 to 23 percent), and altered bowel habits with either constipation or diarrhea (20 percent) [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/1,6,10\" class=\"abstract_t\">1,6,10</a>]. Based on the severity, the duration of the symptoms varies from days to years prior to the diagnosis [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/1\" class=\"abstract_t\">1</a>]. </p><p>An abdominal mass can be palpated in 35 to 50 percent of patients. Masses tend to be deep-seated and poorly defined [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/3,4,6,10,11\" class=\"abstract_t\">3,4,6,10,11</a>]. Other findings include abdominal tenderness in about one-third of cases and distension in about 10 to 15 percent. Signs of peritoneal inflammation and ascites (usually chylous) are rare. </p><p>Patients may also have signs and symptoms attributable to associated conditions, such as underlying malignancy (eg, pleural effusion, fever, edema due to protein-losing enteropathy, hemolytic anemia, jaundice due to biliary obstruction) [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/17,18,35-40\" class=\"abstract_t\">17,18,35-40</a>]. (See <a href=\"#H3\" class=\"local\">'Etiology and pathogenesis'</a> above.)</p><p class=\"headingAnchor\" id=\"H683633133\"><span class=\"h2\">Complications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with sclerosing mesenteritis can present with symptoms associated with complications. These complications include: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bowel obstruction (24 percent) (see <a href=\"topic.htm?path=epidemiology-clinical-features-and-diagnosis-of-mechanical-small-bowel-obstruction-in-adults#H413451751\" class=\"medical medical_review\">&quot;Epidemiology, clinical features, and diagnosis of mechanical small bowel obstruction in adults&quot;, section on 'Clinical presentations'</a> and <a href=\"topic.htm?path=overview-of-mechanical-colorectal-obstruction#H194983524\" class=\"medical medical_review\">&quot;Overview of mechanical colorectal obstruction&quot;, section on 'Clinical presentations'</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Obstructive <span class=\"nowrap\">uropathy/renal</span> failure (24 percent) (see <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-urinary-tract-obstruction-and-hydronephrosis#H2\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of urinary tract obstruction and hydronephrosis&quot;, section on 'Clinical presentation'</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chylous ascites (14 percent) (see <a href=\"topic.htm?path=evaluation-of-adults-with-ascites#H25272225\" class=\"medical medical_review\">&quot;Evaluation of adults with ascites&quot;, section on 'Clinical manifestations'</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chronic mesenteric ischemia (3 percent) [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/10\" class=\"abstract_t\">10</a>] (see <a href=\"topic.htm?path=chronic-mesenteric-ischemia#H23493586\" class=\"medical medical_review\">&quot;Chronic mesenteric ischemia&quot;, section on 'Clinical features'</a>).</p><p/><p class=\"headingAnchor\" id=\"H3300327436\"><span class=\"h2\">Laboratory findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The erythrocyte sedimentation rate and C-reactive protein level may be elevated in approximately 80 percent of patients [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/41\" class=\"abstract_t\">41</a>]. Other non-specific abnormalities include anemia (16 percent) and hypoalbuminemia (5 percent) [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/11\" class=\"abstract_t\">11</a>]. (See <a href=\"#H2733343658\" class=\"local\">'Monitoring response to treatment'</a> below.)</p><p class=\"headingAnchor\" id=\"H814843058\"><span class=\"h2\">Incidental imaging findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Abdominal radiographs, barium enema, and ultrasound are not diagnostic for sclerosing mesenteritis. Plain radiographs can demonstrate signs of mechanical obstruction of the small bowel, colon, or both. Barium enema of the gastrointestinal tract may demonstrate fixation, angulation, thumbprinting, separation, tethering of the bowel, and concentric bowel strictures with tapered, serrated edges [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/42\" class=\"abstract_t\">42</a>]. An abdominal ultrasound may reveal a focal mass lesion [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/43\" class=\"abstract_t\">43</a>]. </p><p>Abdominal computed tomography is the imaging modality of choice but has low specificity for sclerosing mesenteritis. (See <a href=\"#H163211646\" class=\"local\">'Diagnostic imaging'</a> below.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">DIAGNOSIS</span></p><p class=\"headingAnchor\" id=\"H2763634542\"><span class=\"h2\">General approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sclerosing mesenteritis is rare and is usually discovered incidentally on abdominal imaging for evaluation of nonspecific abdominal or systemic symptoms (eg, abdominal pain, altered bowel habits, fever, or weight loss) [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/9,34\" class=\"abstract_t\">9,34</a>]. In a patient with these abdominal or systemic symptoms, a presumptive diagnosis of sclerosing mesenteritis can be based on abdominal computerized tomogram findings of a fat ring or halo sign and pseudocapsule. However, a definitive diagnosis of sclerosing mesenteritis requires histologic evaluation to rule out other etiologies. A laparoscopy or laparotomy is usually necessary to obtain tissue. A significant proportion of image-guided percutaneous biopsies are non-diagnostic because fine-needle aspiration specimens often lack sufficient architectural representation to exclude malignancy [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/44\" class=\"abstract_t\">44</a>]. (See <a href=\"#H14\" class=\"local\">'Differential Diagnosis'</a> below.) </p><p>Pathologic confirmation should be obtained in all cases of suspected sclerosing mesenteritis with a mass lesion or pathologic appearing lymphadenopathy. However, the role of biopsy in patients with only mesenteric inflammation (misty mesentery) is controversial. We do not pursue a biopsy for a definitive diagnosis in such cases as the risks of biopsy outweigh the benefits. (See <a href=\"#H163211646\" class=\"local\">'Diagnostic imaging'</a> below.)</p><p class=\"headingAnchor\" id=\"H163211646\"><span class=\"h2\">Diagnostic imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dual-phase abdominal computed tomography (CT) scan is the most sensitive imaging modality for detecting sclerosing mesenteritis. The CT appearance of sclerosing mesenteritis varies depending upon the extent and severity of inflammation and fibrosis [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/9,10\" class=\"abstract_t\">9,10</a>]. However, many of the radiologic features are nonspecific. (See <a href=\"#H14\" class=\"local\">'Differential Diagnosis'</a> below.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Soft tissue mass</strong> &ndash; A soft tissue mass in the root of the small bowel mesentery is present in approximately 60 percent of patients with sclerosing mesenteritis [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/10\" class=\"abstract_t\">10</a>]. Mass lesions may be homogeneous (more fibrotic lesions) or heterogeneous (more inflammatory). In one large series, focal lesions ranged from 1 to 40 cm in size, with a mean of 10 cm [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/6\" class=\"abstract_t\">6</a>]. For unclear reasons, the jejunal mesentery seems to be most commonly involved, although cases involving the sigmoid mesocolon have also been described. Focal infiltration may also occur in the region of the pancreas, simulating a primary pancreatic malignancy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Fat ring and tumor pseudocapsule</strong> &ndash; Fat ring (or halo) sign and tumor pseudocapsule are considered to be somewhat specific for mesenteric panniculitis [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/16,45-50\" class=\"abstract_t\">16,45-50</a>]. The fat ring or halo sign describes the preservation of the densitometric values of fat nearest the mesenteric vessels and is seen in 56 to 90 percent of patients with sclerosing mesenteritis (<a href=\"image.htm?imageKey=GAST%2F114835\" class=\"graphic graphic_diagnosticimage graphicRef114835 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/16,45-50\" class=\"abstract_t\">16,45-50</a>]. A tumor pseudocapsule, seen in up to 60 percent of patients, refers to the finding of a hyperattenuated stripe partly surrounding the inflammation. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Vascular abnormalities</strong> &ndash; Vascular displacement, encasement, or thrombosis may be seen in over one-half of cases [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/16,45-50\" class=\"abstract_t\">16,45-50</a>]. Multidetector CT with three-dimensional volume rendering can provide information about the relationship between mesenteric mass lesions and surrounding vasculature [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/51\" class=\"abstract_t\">51</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Calcifications</strong> &ndash; Calcifications are present within approximately 20 percent of lesions and probably result from fat necrosis. Cystic components may be present, possibly from focal necrosis due to vascular obstruction. Lymphadenopathy (mesenteric or retroperitoneal) is present in 20 to 40 percent of patients [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/45,52\" class=\"abstract_t\">45,52</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Misty mesentery</strong> &ndash; Misty mesentery has been used to describe the finding of increased attenuation of mesenteric fat with small lymph nodes but without evidence of a discrete mass [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/53,54\" class=\"abstract_t\">53,54</a>]. The increased attenuation is due to infiltration by inflammatory cells, fluid (edema, blood, lymph), tumor, or fibrosis. Thus, it is not specific for sclerosing mesenteritis, because hemorrhage, edema, or malignancy (particularly lymphoma) can present in an identical fashion. </p><p/><p>Magnetic resonance imaging has not been extensively studied in patients with sclerosing mesenteritis, although the findings appear to be similar to CT [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/55-58\" class=\"abstract_t\">55-58</a>]. Positron emission tomography scan cannot reliably differentiate sclerosing mesenteritis from involvement of the mesentery with tumor in patients with cancer and therefore does not have a role in the evaluation of patients with sclerosing mesenteritis [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/59,60\" class=\"abstract_t\">59,60</a>]. </p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Pathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although gross findings are variable, three general patterns of mesenteric thickening have been observed [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/2,6\" class=\"abstract_t\">2,6</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Type I (42 percent of cases) &ndash; diffuse mesenteric thickening</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Type II (32 percent of cases) &ndash; a single discrete mass</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Type III (26 percent of cases) &ndash; multiple discrete mass lesions</p><p/><p>The pattern of mesenteric thickening has not been associated with response to therapy or prognosis, so its clinical application is limited.</p><p>The most consistent histologic findings of sclerosing mesenteritis are fibrosis and chronic inflammation [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/6\" class=\"abstract_t\">6</a>]. Granulomas are generally not part of the histologic spectrum, but may be present in patients with a history of trauma or foreign bodies.</p><p>Flow cytometry is used if lymphoma cannot be excluded on histologic evaluation. Immunohistochemical staining for <span class=\"nowrap\">CD117/c-kit,</span> beta catenin, and smooth muscle actin has been proposed for distinguishing sclerosing mesenteritis from gastrointestinal stromal tumors (GIST) and mesenteric fibromatosis [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/61\" class=\"abstract_t\">61</a>]. Unlike GIST and mesenteric fibromatosis, sclerosing mesenteritis does not stain for <span class=\"nowrap\">CD117/c-kit</span> and beta catenin, respectively, but retains staining for smooth muscle actin. (See <a href=\"topic.htm?path=epidemiology-classification-clinical-presentation-prognostic-features-and-diagnostic-work-up-of-gastrointestinal-stromal-tumors-gist\" class=\"medical medical_review\">&quot;Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal stromal tumors (GIST)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of sclerosing mesenteritis is broad and includes other processes that can affect the mesentery (<a href=\"image.htm?imageKey=GAST%2F81532\" class=\"graphic graphic_table graphicRef81532 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/1-6,16,46,62-67\" class=\"abstract_t\">1-6,16,46,62-67</a>]. The most common mimics are lymphoma, mesenteric carcinomatosis, carcinoid tumor, mesenteric fibromatosis, and mesenteric edema. Mesenteric edema can be caused by a number of conditions, including hypoalbuminemia, cirrhosis, congestive heart failure, and trauma. </p><p>The following features can help narrow the differential diagnosis:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Non-Hodgkin lymphoma (NHL) may present as a nodal mass in the mesentery. However, features supportive of NHL include the presence of retroperitoneal lymphadenopathy, splenomegaly and lack of tumoral calcification. In addition, the fat ring that can be seen in sclerosing mesenteritis is absent in NHL. (See <a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-primary-gastrointestinal-lymphomas\" class=\"medical medical_review\">&quot;Clinical presentation and diagnosis of primary gastrointestinal lymphomas&quot;</a> and <a href=\"#H163211646\" class=\"local\">'Diagnostic imaging'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Carcinoid tumors may be associated with a misty mesentery and poorly defined mesenteric mass lesions, which arise in the setting of a desmoplastic tumor reaction. However, the presence of focal bowel lesions and liver lesions supports the diagnosis of carcinoid. (See <a href=\"topic.htm?path=diagnosis-of-the-carcinoid-syndrome-and-tumor-localization#H31868282\" class=\"medical medical_review\">&quot;Diagnosis of the carcinoid syndrome and tumor localization&quot;, section on 'Computed tomography'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Peritoneal carcinomatosis is usually associated with ascites and multiple enhancing mesenteric, peritoneal, <span class=\"nowrap\">and/or</span> omental nodules. (See <a href=\"topic.htm?path=malignancy-related-ascites#H7\" class=\"medical medical_review\">&quot;Malignancy-related ascites&quot;, section on 'Imaging tests'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mesenteric fibromatosis (desmoid tumors) are tumor-like fibromatoses that are most commonly found in patients with familial adenomatous polyposis (FAP). These lesions can be distinguished from sclerosing mesenteritis on the basis of a paucity of inflammation and a tendency to involve the bowel muscularis propria. In addition, desmoid tumors tend to be multifocal and commonly recur following resection. Desmoids also lack the dense sclerosis more commonly found in sclerosing mesenteritis. (See <a href=\"topic.htm?path=desmoid-tumors-epidemiology-risk-factors-molecular-pathogenesis-clinical-presentation-diagnosis-and-local-therapy#H11\" class=\"medical medical_review\">&quot;Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy&quot;, section on 'Clinical presentation and diagnosis'</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis#H534324085\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of familial adenomatous polyposis&quot;, section on 'FAP variants'</a>.)</p><p/><p>The differential diagnosis of abdominal pain is discussed in detail separately. (See <a href=\"topic.htm?path=causes-of-abdominal-pain-in-adults\" class=\"medical medical_review\">&quot;Causes of abdominal pain in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">NATURAL HISTORY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The natural history of sclerosing mesenteritis is not well understood in part because of the rarity of this condition, the disparate nomenclature used in the literature, and lack of adequate follow-up. Although there are case reports of fatalities and patients with aggressive disease phenotypes, the breadth of clinical experience suggests a benign, stable, or slowly progressive course in approximately 80 percent of patients [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/68\" class=\"abstract_t\">68</a>]. Cases of spontaneous regression have been reported, with times to resolution of the abdominal mass ranging from a few weeks to over a decade [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/1,69\" class=\"abstract_t\">1,69</a>]. </p><p>Approximately 20 percent of patients with sclerosing mesenteritis develop complications [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/6,11\" class=\"abstract_t\">6,11</a>]. Fulminant cases of sclerosing mesenteritis have been reported and are largely due to complications of intestinal obstruction [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/70\" class=\"abstract_t\">70</a>]. Other complications include mesenteric vascular occlusion (both arterial and venous), chylous ascites, and adverse effects from medications used to treat sclerosing mesenteritis. (See <a href=\"#H683633133\" class=\"local\">'Complications'</a> above and <a href=\"#H1989275014\" class=\"local\">'Non-obstructive symptoms'</a> below.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h1\">APPROACH TO MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no uniformly recognized standard therapy for sclerosing mesenteritis. Our approach to management is based on the type and severity of symptoms (<a href=\"image.htm?imageKey=GAST%2F115883\" class=\"graphic graphic_algorithm graphicRef115883 \">algorithm 1</a>).</p><p class=\"headingAnchor\" id=\"H696432160\"><span class=\"h2\">Whom to treat</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The primary goal of therapy is the relief of symptoms. Therapy has not been shown to clearly improve prognosis or prevent progression or the development of complications. Patients who present with asymptomatic disease are likely to remain asymptomatic during follow-up, and do not require treatment. </p><p>Therapy should be offered to patients with symptoms of sclerosing mesenteritis or its complications (eg, small bowel obstruction, chylous ascites and chronic mesenteric ischemia). (See <a href=\"#H15\" class=\"local\">'Natural history'</a> above and <a href=\"#H2935853926\" class=\"local\">'Clinical features'</a> above and <a href=\"#H2210375314\" class=\"local\">'Obstructive symptoms'</a> below.)</p><p class=\"headingAnchor\" id=\"H3693079295\"><span class=\"h2\">Pre-treatment considerations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We typically perform the following studies prior to initiating therapy:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complete blood count</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Erythrocyte sedimentation rate and C-reactive protein</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Blood glucose</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Urinalysis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Blood urea nitrogen and serum creatinine</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Liver tests including aminotransferases, alkaline phosphatase, and bilirubin </p><p/><p>Before starting <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>, it is prudent to screen patients for mutations in the thiopurine methyltransferase (TPMT) gene that causes TPMT deficiency. One in 300 individuals are homozygous for a mutant allele and have very low or absent enzyme levels. These patients should not receive azathioprine because they cannot metabolize the drug and may develop life-threatening bone marrow suppression. (See <a href=\"topic.htm?path=6-mercaptopurine-6-mp-metabolite-monitoring-and-tpmt-testing-in-patients-with-inflammatory-bowel-disease#H2\" class=\"medical medical_review\">&quot;6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in patients with inflammatory bowel disease&quot;, section on 'TPMT enzyme determination'</a>.)</p><p>Specific interactions with other medications may be determined using the drug interactions program (Lexi-Interact) included with UpToDate. This tool can be accessed from the Drug Interactions link in the top right corner of your browser window in UpToDate online, or through the individual drug information monographs in the section &quot;Drug Interactions.&quot;</p><p class=\"headingAnchor\" id=\"H2210375314\"><span class=\"h2\">Obstructive symptoms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with bowel obstruction are managed conservatively when feasible. Surgical bypass may be indicated to alleviate symptoms in those whose symptoms are dominated by focal intestinal obstruction [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/1-4,71\" class=\"abstract_t\">1-4,71</a>]. In the vast majority of cases, complete surgical resection is impossible because of associated vascular compromise and disease extent. (See <a href=\"topic.htm?path=overview-of-management-of-mechanical-small-bowel-obstruction-in-adults\" class=\"medical medical_review\">&quot;Overview of management of mechanical small bowel obstruction in adults&quot;</a> and <a href=\"topic.htm?path=overview-of-mechanical-colorectal-obstruction\" class=\"medical medical_review\">&quot;Overview of mechanical colorectal obstruction&quot;</a>.)</p><p>Patients with symptoms of chronic mesenteric ischemia due to obstructed mesenteric arteries or veins require revascularization. However, endovascular revascularization is possible only in a minority of patients due to the length or distal arterial location of the stenosis. Open surgical techniques for mesenteric revascularization are rarely feasible due to the disease extent. Radiation therapy has had equivocal success [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/7,72\" class=\"abstract_t\">7,72</a>]. (See <a href=\"topic.htm?path=chronic-mesenteric-ischemia#H5\" class=\"medical medical_review\">&quot;Chronic mesenteric ischemia&quot;, section on 'Management'</a>.)</p><p>Surgery does not cure sclerosing mesenteritis. In one study, 10 percent of patients who underwent surgery required no additional treatment [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/10\" class=\"abstract_t\">10</a>]. Recurrent disease can manifest by radiologic findings in patients with clinical symptoms. In patients with persistent or recurrent symptoms following surgery, we suggest medical management similar to patients with non-obstructive symptoms. (See <a href=\"#H1586262917\" class=\"local\">'Initial treatment'</a> below.)</p><p class=\"headingAnchor\" id=\"H1989275014\"><span class=\"h2\">Non-obstructive symptoms</span></p><p class=\"headingAnchor\" id=\"H1586262917\"><span class=\"h3\">Initial treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We use glucocorticoids (<a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> 40 mg daily) and <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> (10 mg twice daily) as initial medical therapy in patients with symptomatic sclerosing mesenteritis. In patients with symptomatic improvement at three months, prednisone is tapered gradually over three months. Tamoxifen is continued indefinitely in patients with sustained symptomatic improvement (<a href=\"image.htm?imageKey=GAST%2F115883\" class=\"graphic graphic_algorithm graphicRef115883 \">algorithm 1</a>). A number of immunosuppressive agents have been used in an attempt to stabilize the disease. However, there are limited data from case series to support their use in controlling symptoms of sclerosing mesenteritis and these agents have not been directly compared. Alternative treatment approaches may be required for patients who cannot tolerate tamoxifen due to side-effects or have contraindications to tamoxifen. (See <a href=\"#H1662276371\" class=\"local\">'Alternative approaches and refractory disease'</a> below.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Glucocorticoids</strong> &ndash; Glucocorticoids alone, and in combination with <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>, or <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> has been associated with symptomatic improvement [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/10,24,26-28\" class=\"abstract_t\">10,24,26-28</a>]. Patients with the greatest inflammatory component, as demonstrated by the acuity of presentation with fever, weight loss, malaise, elevated erythrocyte sedimentation rate, and prominent inflammation on biopsy, appear to be the most responsive. Due to frequent steroid-related side effects, long-term treatment with glucocorticoids is not recommended. (See <a href=\"#H1506324249\" class=\"local\">'Duration of therapy in responders'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hormonal</strong> <strong>therapy</strong> &ndash; <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">Tamoxifen</a> is a selective estrogen receptor modulator. A proposed mechanism of benefit from tamoxifen is the inhibition of fibroblast TGF-beta1 production [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/73\" class=\"abstract_t\">73</a>]. A response to hormonal therapy with tamoxifen and rarely <a href=\"topic.htm?path=progesterone-drug-information\" class=\"drug drug_general\">progesterone</a> has been described in case reports [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/74,75\" class=\"abstract_t\">74,75</a>]. In one series of 92 patients with sclerosing mesenteritis, in which 20 patients were treated with combination therapy with tamoxifen plus glucocorticoids, symptomatic improvement was reported in 12 patients (60 percent) within 12 to 16 weeks [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/10\" class=\"abstract_t\">10</a>]. Among eight patients without improvement, persistent symptoms and progressive symptoms were reported in six (30 percent) and two (10 percent), respectively. Tamoxifen is associated with an increased risk of uterine cancer. Other side effects associated with the use of tamoxifen include hot flashes, vaginal discharge, menstrual irregularities, sexual dysfunction, and venous thromboembolism. (See <a href=\"topic.htm?path=managing-the-side-effects-of-tamoxifen\" class=\"medical medical_review\">&quot;Managing the side effects of tamoxifen&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2733343658\"><span class=\"h3\">Monitoring response to treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Response to therapy is assessed by symptom improvement. Erythrocyte sedimentation rate and C-reactive protein level are neither sensitive nor specific and treatment decisions are generally based on symptoms alone [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/41\" class=\"abstract_t\">41</a>]. Radiologic improvement occurs in the minority of patients and often does not correlate with symptomatic response to treatment. We therefore do not perform follow-up abdominal CT scans unless clinically warranted.</p><p>There are limited data on the predictors of treatment response in patients with sclerosing mesenteritis. In a systematic review of 192 reported cases of sclerosing mesenteritis, symptom duration of greater than one month, the presence of an underlying autoimmune disorder, or low serum protein were associated with a poor response to medical treatment that predominantly consisted of glucocorticoids [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/11\" class=\"abstract_t\">11</a>]. In contrast, patients with abdominal tenderness or leukocytosis at presentation were more likely to have a good response to treatment. </p><p class=\"headingAnchor\" id=\"H1506324249\"><span class=\"h3\">Duration of therapy in responders</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with symptomatic response to initial treatment with <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> (40 mg daily for three months) and <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a>, we gradually taper prednisone over three months. We continue tamoxifen indefinitely in patients who respond and are tolerating treatment.</p><p class=\"headingAnchor\" id=\"H1662276371\"><span class=\"h3\">Alternative approaches and refractory disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients whose symptoms do not respond to <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a>, who cannot tolerate tamoxifen due to side-effects, or who have contraindications to tamoxifen, we use <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a> or <a href=\"topic.htm?path=pentoxifylline-drug-information\" class=\"drug drug_general\">pentoxifylline</a> (<a href=\"image.htm?imageKey=GAST%2F115883\" class=\"graphic graphic_algorithm graphicRef115883 \">algorithm 1</a>). Given the side-effect profile of <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>, we reserve its use for patients that are refractory to azathioprine and pentoxifylline. We use <a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">thalidomide</a> in patients with sclerosing mesenteritis who do not respond to other treatment options. Data to support these agents are limited to small case series and studies comparing them are lacking. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">Azathioprine</a><strong> &ndash; </strong>We use azathioprine (2 to 2.5 <span class=\"nowrap\">mg/kg/d)</span> in patients who are refractory to <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a>. However, it may be used as an alternative to tamoxifen (<a href=\"image.htm?imageKey=GAST%2F115883\" class=\"graphic graphic_algorithm graphicRef115883 \">algorithm 1</a>). The major limitation of azathioprine is the slow response to treatment. Combination treatment with glucocorticoids followed by azathioprine offers the advantage of relatively rapid improvement while avoiding the long-term consequences of glucocorticoid treatment. Side effects include bone marrow suppression, infections, nausea, pancreatitis, and an increased risk of lymphoma and skin cancers.</p><p/><p class=\"bulletIndent1\">In an observational study that included 92 patients with sclerosing mesenteritis, treatment included medical therapy alone in 24 patients, surgery alone in 12, surgery followed by medical therapy in 8, and 48 patients (52 percent) received no treatment [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/10\" class=\"abstract_t\">10</a>]. Medical treatment consisted of treatment with one or more of the pharmacologic agents for a treatment duration that ranged from 4 to 36 months. Agents used included <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a>, <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a>, <a href=\"topic.htm?path=budesonide-drug-information\" class=\"drug drug_general\">budesonide</a>, <a href=\"topic.htm?path=colchicine-drug-information\" class=\"drug drug_general\">colchicine</a>, <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>, <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, and <a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">thalidomide</a>. Symptomatic improvement was noted in 12 of 20 patients (60 percent) treated with tamoxifen in combination with prednisone. Of the 12 patients treated with non-tamoxifen&ndash;based regimens, one of two patients treated with prednisone, azathioprine, and colchicine responded to treatment. Two patients treated with other regimens (prednisone, azathioprine, and thalidomide; and prednisone and colchicine) had <span class=\"nowrap\">persistent/progressive</span> disease. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=pentoxifylline-drug-information\" class=\"drug drug_general\">Pentoxifylline</a><strong> </strong>&ndash;<strong> </strong>Pentoxifylline has weak anti-inflammatory and possibly anti-fibrotic properties. It can be used as an alternative to <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a> and in patients refractory to azathioprine. In the author&rsquo;s experience of 13 patients<strong> </strong>with sclerosing mesenteritis treated with pentoxifylline for a varying duration, six (46 percent) had at least partial symptom improvement [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/29\" class=\"abstract_t\">29</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">Cyclophosphamide</a> &ndash; Cyclophosphamide is an alkylating agent that reduces proliferation of both B and T cells. Cyclophosphamide has several serious potential side effects. </p><p/><p class=\"bulletIndent1\">A response to oral <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> was described in two patients, including one who had not responded to glucocorticoids [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/25\" class=\"abstract_t\">25</a>]. Prior to the initiation of therapy, both had a progressive downhill course characterized by prominent systemic symptoms. Initiation of cyclophosphamide (2 <span class=\"nowrap\">mg/kg)</span> resulted in clinical remission for up to 30 months. One of the two patients had complete resolution of the mass at surgical exploration. (See <a href=\"topic.htm?path=general-toxicity-of-cyclophosphamide-in-rheumatic-diseases\" class=\"medical medical_review\">&quot;General toxicity of cyclophosphamide in rheumatic diseases&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=thalidomide-drug-information\" class=\"drug drug_general\">Thalidomide</a> &ndash; Thalidomide has anti-inflammatory, immunomodulatory, and anti-angiogenic properties. In an open-label pilot study of five patients with symptomatic mesenteric panniculitis, treatment with thalidomide (200 <span class=\"nowrap\">mg/day</span> for 12 weeks) was safe and well tolerated [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/41\" class=\"abstract_t\">41</a>]. Although there was no radiologic improvement in post-treatment CT scans, four of five patients experienced an improvement or resolution in symptoms.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=colchicine-drug-information\" class=\"drug drug_general\">Colchicine</a> &ndash; The use of colchicine in sclerosing mesenteritis is controversial. A case report described successful transition to colchicine (1 mg daily) for maintenance therapy in a patient who had responded clinically to glucocorticoids [<a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/76\" class=\"abstract_t\">76</a>]. However, in the author&rsquo;s experience, most patients either do not respond to colchicine or do not tolerate it due to gastrointestinal side effects.</p><p/><p class=\"headingAnchor\" id=\"H22\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sclerosing mesenteritis is a rare, non-neoplastic inflammatory and fibrotic disease that affects the mesentery. Sclerosing mesenteritis can affect the integrity of the gastrointestinal lumen and mesenteric vessels by a mass effect. Sclerosing mesenteritis encompasses a spectrum of idiopathic primary inflammatory and fibrotic processes that affect the mesentery. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above and <a href=\"#H4212209001\" class=\"local\">'Terminology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The clinical presentation ranges from an asymptomatic incidental finding on abdominal imaging to abdominal and systemic symptoms (eg, abdominal pain, altered bowel habits, fever, weight loss) to complications such as intestinal obstruction. Laboratory markers of inflammation (erythrocyte sedimentation rate and C-reactive protein) may be elevated. (See <a href=\"#H8\" class=\"local\">'Clinical presentation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sclerosing mesenteritis is usually discovered incidentally on abdominal imaging for evaluation of non-specific abdominal or systemic symptoms. A presumptive diagnosis of sclerosing mesenteritis can be based on abdominal computerized tomogram findings of a fat ring or halo sign and pseudocapsule (<a href=\"image.htm?imageKey=GAST%2F114835\" class=\"graphic graphic_diagnosticimage graphicRef114835 \">image 1</a>). However, a definitive diagnosis of sclerosing mesenteritis requires histologic evaluation to rule out other etiologies. (See <a href=\"#H11\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Approximately 20 percent of patients with sclerosing mesenteritis develop complications. Fulminant cases of sclerosing mesenteritis have been reported and are largely due to complications of intestinal obstruction. Other complications include mesenteric vascular occlusion (both arterial and venous), chylous ascites, and adverse effects from medications used to treat sclerosing mesenteritis. (See <a href=\"#H15\" class=\"local\">'Natural history'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Management is based on the presence of symptoms due to sclerosing mesenteritis or its complications (<a href=\"image.htm?imageKey=GAST%2F115883\" class=\"graphic graphic_algorithm graphicRef115883 \">algorithm 1</a>). Patients with asymptomatic disease do not require treatment. The primary goal of therapy is the relief of symptoms. In patients who are symptomatic, we suggest a trial of medical therapy (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). We use glucocorticoids in combination with <a href=\"topic.htm?path=tamoxifen-drug-information\" class=\"drug drug_general\">tamoxifen</a> as first-line therapy. In patients who fail to respond to tamoxifen, we use <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a> or <a href=\"topic.htm?path=pentoxifylline-drug-information\" class=\"drug drug_general\">pentoxifylline</a>. Given the side-effect profile of <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a>, we reserve its use for patients that are refractory to azathioprine and pentoxifylline. The role of surgery in sclerosing mesenteritis is limited to selected patients with obstructive complications. (See <a href=\"#H16\" class=\"local\">'Approach to management'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/1\" class=\"nounderline abstract_t\">Durst AL, Freund H, Rosenmann E, Birnbaum D. Mesenteric panniculitis: review of the leterature and presentation of cases. Surgery 1977; 81:203.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/2\" class=\"nounderline abstract_t\">Kipfer RE, Moertel CG, Dahlin DC. Mesenteric lipodystrophy. Ann Intern Med 1974; 80:582.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/3\" class=\"nounderline abstract_t\">Monahan DW, Poston WK Jr, Brown GJ. Mesenteric panniculitis. South Med J 1989; 82:782.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/4\" class=\"nounderline abstract_t\">Parra-Davila E, McKenney MG, Sleeman D, et al. Mesenteric panniculitis: case report and literature review. Am Surg 1998; 64:768.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/5\" class=\"nounderline abstract_t\">Kelly JK, Hwang WS. Idiopathic retractile (sclerosing) mesenteritis and its differential diagnosis. Am J Surg Pathol 1989; 13:513.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/6\" class=\"nounderline abstract_t\">Emory TS, Monihan JM, Carr NJ, Sobin LH. Sclerosing mesenteritis, mesenteric panniculitis and mesenteric lipodystrophy: a single entity? Am J Surg Pathol 1997; 21:392.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/7\" class=\"nounderline abstract_t\">OGDEN WW 2nd, BRADBURN DM, RIVES JD. MESENTERIC PANNICULITIS: REVIEW OF 27 CASES. Ann Surg 1965; 161:864.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/8\" class=\"nounderline abstract_t\">Khachaturian T, Hughes J. Mesenteric panniculitis. West J Med 1988; 148:700.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/9\" class=\"nounderline abstract_t\">Daskalogiannaki M, Voloudaki A, Prassopoulos P, et al. CT evaluation of mesenteric panniculitis: prevalence and associated diseases. AJR Am J Roentgenol 2000; 174:427.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/10\" class=\"nounderline abstract_t\">Akram S, Pardi DS, Schaffner JA, Smyrk TC. Sclerosing mesenteritis: clinical features, treatment, and outcome in ninety-two patients. Clin Gastroenterol Hepatol 2007; 5:589.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/11\" class=\"nounderline abstract_t\">Sharma P, Yadav S, Needham CM, Feuerstadt P. Sclerosing mesenteritis: a systematic review of 192 cases. Clin J Gastroenterol 2017; 10:103.</a></li><li class=\"breakAll\">Adams JT. Abdominal wall, omentum, mesentry, and retroperitoneum. In: Principles of Surgery, 6th ed, Schwartz S, Shires F, Spencer F (Eds), McGraw Hill, New York 1994. p.1485.</li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/13\" class=\"nounderline abstract_t\">Jura V. Sulla mesenterite retratile e sclerosante. Policlinico (Sez. Chir.) 1924; 31:575.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/14\" class=\"nounderline abstract_t\">van der Hulst RW, Rauws EA, Tytgat GN. Mesenteritis secondary to the use of a pneumatic jackhammer. Eur J Gastroenterol Hepatol 1995; 7:573.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/15\" class=\"nounderline abstract_t\">Mathew J, McKenna F, Mason J, et al. Sclerosing mesenteritis with occult ileal perforation: report of a case simulating extensive intra-abdominal malignancy. Dis Colon Rectum 2004; 47:1974.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/16\" class=\"nounderline abstract_t\">Horton KM, Lawler LP, Fishman EK. CT findings in sclerosing mesenteritis (panniculitis): spectrum of disease. Radiographics 2003; 23:1561.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/17\" class=\"nounderline abstract_t\">Papadaki HA, Kouroumalis EA, Stefanaki K, et al. Retractile mesenteritis presenting as fever of unknown origin and autoimmune haemolytic anaemia. Digestion 2000; 61:145.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/18\" class=\"nounderline abstract_t\">Vidarsson B, Matth&iacute;asson P, Agnarsson BA, Onundarson PT. Mesenteric panniculitis presenting with autoimmune haemolytic anaemia. Acta Haematol 2002; 107:35.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/19\" class=\"nounderline abstract_t\">Vernace MA, Bellucci AG, Mossey RT, et al. Minimal change nephropathy associated with sclerosing mesenteritis. Nephron 1996; 73:473.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/20\" class=\"nounderline abstract_t\">Dor AM, Kohler JL, Aubrespy P, et al. [Mesenteric panniculitis, an unusual initial stage of acute lupus erythematosus in a ten-year old girl (author's transl)]. Arch Anat Cytol Pathol 1982; 30:121.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/21\" class=\"nounderline abstract_t\">Sauvaget F, Piette JC, Galezowski N, et al. [Relapsing polychondritis and mesenteric panniculitis: apropos of 2 cases]. Rev Med Interne 1993; 14:253.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/22\" class=\"nounderline abstract_t\">Arroyo-&Aacute;vila M, Vil&aacute; LM. Limited systemic sclerosis initially presenting with mesenteric panniculitis. BMJ Case Rep 2014; 2014.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/23\" class=\"nounderline abstract_t\">Garrido A, Verdejo C, M&aacute;rquez JL, et al. [Intestinal lymphoma and mesenteric panniculitis: complications of undiagnosed celiac disease]. Gastroenterol Hepatol 2008; 31:221.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/24\" class=\"nounderline abstract_t\">Bala A, Coderre SP, Johnson DR, Nayak V. Treatment of sclerosing mesenteritis with corticosteroids and azathioprine. Can J Gastroenterol 2001; 15:533.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/25\" class=\"nounderline abstract_t\">Bush RW, Hammar SP Jr, Rudolph RH. Sclerosing mesenteritis. Response to cyclophosphamide. Arch Intern Med 1986; 146:503.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/26\" class=\"nounderline abstract_t\">G&eacute;n&eacute;reau T, Bellin MF, Wechsler B, et al. Demonstration of efficacy of combining corticosteroids and colchicine in two patients with idiopathic sclerosing mesenteritis. Dig Dis Sci 1996; 41:684.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/27\" class=\"nounderline abstract_t\">Kikiros CS, Edis AJ. Mesenteric panniculitis resulting in bowel obstruction: response to steroids. Aust N Z J Surg 1989; 59:287.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/28\" class=\"nounderline abstract_t\">Tytgat GN, Roozendaal K, Winter W, Esseveld MR. Successful treatment of a patient with retractile mesenteritis with prednisone and azathioprine. Gastroenterology 1980; 79:352.</a></li><li class=\"breakAll\">Pardi, DS, Rochester, MN, 2017, personal communication.</li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/30\" class=\"nounderline abstract_t\">Scheer F, Spunar P, Wiggermann P, et al. Mesenteric Panniculitis (MP) in CT - A Predictor of Malignancy? Rofo 2016; 188:926.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/31\" class=\"nounderline abstract_t\">Goh J, Otridge B, Brady H, et al. Aggressive multiple myeloma presenting as mesenteric panniculitis. Am J Gastroenterol 2001; 96:238.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/32\" class=\"nounderline abstract_t\">G&ouml;gebakan &Ouml;, Albrecht T, Osterhoff MA, Reimann A. Is mesenteric panniculitis truely a paraneoplastic phenomenon? A matched pair analysis. Eur J Radiol 2013; 82:1853.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/33\" class=\"nounderline abstract_t\">TEDESCHI CG, BOTTA GC. Retractile mesenteritis. N Engl J Med 1962; 266:1035.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/34\" class=\"nounderline abstract_t\">Hirano H, Yoshida A, Sasae Y, et al. Mesenteric panniculitis: a rare cause of fever. Int J Rheum Dis 2012; 15:e40.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/35\" class=\"nounderline abstract_t\">Harris RJ, van Stolk RU, Church JM, Kavuru MS. Thoracic mesothelioma associated with abdominal mesenteric panniculitis. Am J Gastroenterol 1994; 89:2240.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/36\" class=\"nounderline abstract_t\">Medina-Franco H, Listinsky C, Mel Wilcox C, et al. Concomitant sclerosing mesenteritis and bile duct fibrosis simulating Klatskin's tumor. J Gastrointest Surg 2001; 5:658.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/37\" class=\"nounderline abstract_t\">Sans M, Varas M, Anglada A, et al. Mesenteric panniculitis presenting as fever of unknown origin. Am J Gastroenterol 1995; 90:1159.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/38\" class=\"nounderline abstract_t\">H&ouml;ring E, Hingerl T, Hens K, et al. Protein-losing enteropathy: first manifestation of sclerosing mesenteritis. Eur J Gastroenterol Hepatol 1995; 7:481.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/39\" class=\"nounderline abstract_t\">Hinds BR, Bahrami S, Bernardi JM, Callen JP. Cutaneous sclerosis: a previously undescribed manifestation of sclerosing mesenteritis. Arch Dermatol 2010; 146:1009.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/40\" class=\"nounderline abstract_t\">Rispo A, Sica M, Bucci L, et al. Protein-loosing enteropathy in sclerosing mesenteritis. Eur Rev Med Pharmacol Sci 2015; 19:477.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/41\" class=\"nounderline abstract_t\">Ginsburg PM, Ehrenpreis ED. A pilot study of thalidomide for patients with symptomatic mesenteric panniculitis. Aliment Pharmacol Ther 2002; 16:2115.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/42\" class=\"nounderline abstract_t\">P&eacute;rez-Font&aacute;n FJ, Soler R, Sanchez J, et al. Retractile mesenteritis involving the colon: barium enema, sonographic, and CT findings. AJR Am J Roentgenol 1986; 147:937.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/43\" class=\"nounderline abstract_t\">Sato M, Ishida H, Konno K, et al. Mesenteric panniculitis: sonographic findings. Abdom Imaging 2000; 25:142.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/44\" class=\"nounderline abstract_t\">Weiser J, Salky B, Slepian A, Dikman S. Laparoscopic diagnosis of retractile mesenteritis. Gastrointest Endosc 1992; 38:615.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/45\" class=\"nounderline abstract_t\">Sabat&eacute; JM, Torrubia S, Maideu J, et al. Sclerosing mesenteritis: imaging findings in 17 patients. AJR Am J Roentgenol 1999; 172:625.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/46\" class=\"nounderline abstract_t\">Sheth S, Horton KM, Garland MR, Fishman EK. Mesenteric neoplasms: CT appearances of primary and secondary tumors and differential diagnosis. Radiographics 2003; 23:457.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/47\" class=\"nounderline abstract_t\">Valls C. Fat-ring sign in sclerosing mesenteritis. AJR Am J Roentgenol 2000; 174:259.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/48\" class=\"nounderline abstract_t\">Okino Y, Kiyosue H, Mori H, et al. Root of the small-bowel mesentery: correlative anatomy and CT features of pathologic conditions. Radiographics 2001; 21:1475.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/49\" class=\"nounderline abstract_t\">Badet N, Sailley N, Briquez C, et al. Mesenteric panniculitis: still an ambiguous condition. Diagn Interv Imaging 2015; 96:251.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/50\" class=\"nounderline abstract_t\">van Putte-Katier N, van Bommel EF, Elgersma OE, Hendriksz TR. Mesenteric panniculitis: prevalence, clinicoradiological presentation and 5-year follow-up. Br J Radiol 2014; 87:20140451.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/51\" class=\"nounderline abstract_t\">Lawler LP, McCarthy DM, Fishman EK, Hruban R. Sclerosing mesenteritis: depiction by multidetector CT and three-dimensional volume rendering. AJR Am J Roentgenol 2002; 178:97.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/52\" class=\"nounderline abstract_t\">Seo M, Okada M, Okina S, et al. Mesenteric panniculitis of the colon with obstruction of the inferior mesenteric vein: report of a case. Dis Colon Rectum 2001; 44:885.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/53\" class=\"nounderline abstract_t\">Mindelzun RE, Jeffrey RB Jr, Lane MJ, Silverman PM. The misty mesentery on CT: differential diagnosis. AJR Am J Roentgenol 1996; 167:61.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/54\" class=\"nounderline abstract_t\">Seo BK, Ha HK, Kim AY, et al. Segmental misty mesentery: analysis of CT features and primary causes. Radiology 2003; 226:86.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/55\" class=\"nounderline abstract_t\">Ghanem N, Pache G, Bley T, et al. MR findings in a rare case of sclerosing mesenteritis of the mesocolon. J Magn Reson Imaging 2005; 21:632.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/56\" class=\"nounderline abstract_t\">Kobayashi S, Takeda K, Tanaka N, et al. Mesenteric panniculitis: MR findings. J Comput Assist Tomogr 1993; 17:500.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/57\" class=\"nounderline abstract_t\">Fujiyoshi F, Ichinari N, Kajiya Y, et al. Retractile mesenteritis: small-bowel radiography, CT, and MR imaging. AJR Am J Roentgenol 1997; 169:791.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/58\" class=\"nounderline abstract_t\">Kronthal AJ, Kang YS, Fishman EK, et al. MR imaging in sclerosing mesenteritis. AJR Am J Roentgenol 1991; 156:517.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/59\" class=\"nounderline abstract_t\">Zissin R, Metser U, Hain D, Even-Sapir E. Mesenteric panniculitis in oncologic patients: PET-CT findings. Br J Radiol 2006; 79:37.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/60\" class=\"nounderline abstract_t\">Nguyen BD. F-18 FDG PET demonstration of sclerosing mesenteritis. Clin Nucl Med 2003; 28:670.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/61\" class=\"nounderline abstract_t\">Montgomery E, Torbenson MS, Kaushal M, et al. Beta-catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis. Am J Surg Pathol 2002; 26:1296.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/62\" class=\"nounderline abstract_t\">Ehrenpreis ED, Roginsky G, Gore RM. Clinical significance of mesenteric panniculitis-like abnormalities on abdominal computerized tomography in patients with malignant neoplasms. World J Gastroenterol 2016; 22:10601.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/63\" class=\"nounderline abstract_t\">McCrystal DJ, O'Loughlin BS, Samaratunga H. Mesenteric panniculitis: a mimic of malignancy. Aust N Z J Surg 1998; 68:237.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/64\" class=\"nounderline abstract_t\">Phillips RH, Carr RA, Preston R, et al. Sclerosing mesenteritis involving the pancreas: two cases of a rare cause of abdominal mass mimicking malignancy. Eur J Gastroenterol Hepatol 1999; 11:1323.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/65\" class=\"nounderline abstract_t\">Wilkinson JM, Nyamekye I, Reed MW, Polacarz S. Advanced gastrointestinal malignancy or benign inflammatory disease? An unusual presentation of sclerosing mesenteritis. Report of a case. Dis Colon Rectum 1994; 37:1155.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/66\" class=\"nounderline abstract_t\">Gilfrich CP, D'Elia G, Black P, et al. Retractile mesenteritis mimicking an adrenal tumor. J Urol 1999; 162:1677.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/67\" class=\"nounderline abstract_t\">Sheikh RA, Prindiville TP, Arenson D, Ruebner BH. Sclerosing mesenteritis seen clinically as pancreatic pseudotumor: two cases and a review. Pancreas 1999; 18:316.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/68\" class=\"nounderline abstract_t\">Coulier B. Mesenteric panniculitis. Part 2: prevalence and natural course: MDCT prospective study. JBR-BTR 2011; 94:241.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/69\" class=\"nounderline abstract_t\">Daumas A, Agostini S, Villeret J, et al. Spontaneous resolution of severe, symptomatic mesocolic panniculitis: a case report. BMC Gastroenterol 2012; 12:59.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/70\" class=\"nounderline abstract_t\">Soergel KH, Hensley GT. Fatal mesenteric panniculitis. Gastroenterology 1966; 51:529.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/71\" class=\"nounderline abstract_t\">Han SY, Koehler RE, Keller FS, et al. Retractile mesenteritis involving the colon: pathologic and radiologic correlation (case report). AJR Am J Roentgenol 1986; 147:268.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/72\" class=\"nounderline abstract_t\">Pallette EM, Pallette EC, Harrington RW. Sclerosing lipogranulomatosis: its several abdominal syndromes. Arch Surg 1967; 94:803.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/73\" class=\"nounderline abstract_t\">Guest S. Tamoxifen therapy for encapsulating peritoneal sclerosis: mechanism of action and update on clinical experiences. Perit Dial Int 2009; 29:252.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/74\" class=\"nounderline abstract_t\">Mazure R, Fernandez Marty P, Niveloni S, et al. Successful treatment of retractile mesenteritis with oral progesterone. Gastroenterology 1998; 114:1313.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/75\" class=\"nounderline abstract_t\">Venkataramani A, Behling CA, Lyche KD. Sclerosing mesenteritis: an unusual cause of abdominal pain in an HIV-positive patient. Am J Gastroenterol 1997; 92:1059.</a></li><li><a href=\"https://www.uptodate.com/contents/sclerosing-mesenteritis/abstract/76\" class=\"nounderline abstract_t\">Iwanicki-Caron I, Savoye G, Legros JR, et al. Successful management of symptoms of steroid-dependent mesenteric panniculitis with colchicine. Dig Dis Sci 2006; 51:1245.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2602 Version 16.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H22\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H4212209001\" id=\"outline-link-H4212209001\">TERMINOLOGY</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">ETIOLOGY AND PATHOGENESIS</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">CLINICAL PRESENTATION</a><ul><li><a href=\"#H2935853926\" id=\"outline-link-H2935853926\">Clinical features</a></li><li><a href=\"#H683633133\" id=\"outline-link-H683633133\">Complications</a></li><li><a href=\"#H3300327436\" id=\"outline-link-H3300327436\">Laboratory findings</a></li><li><a href=\"#H814843058\" id=\"outline-link-H814843058\">Incidental imaging findings</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">DIAGNOSIS</a><ul><li><a href=\"#H2763634542\" id=\"outline-link-H2763634542\">General approach</a></li><li><a href=\"#H163211646\" id=\"outline-link-H163211646\">Diagnostic imaging</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Pathology</a></li></ul></li><li><a href=\"#H14\" id=\"outline-link-H14\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">NATURAL HISTORY</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">APPROACH TO MANAGEMENT</a><ul><li><a href=\"#H696432160\" id=\"outline-link-H696432160\">Whom to treat</a></li><li><a href=\"#H3693079295\" id=\"outline-link-H3693079295\">Pre-treatment considerations</a></li><li><a href=\"#H2210375314\" id=\"outline-link-H2210375314\">Obstructive symptoms</a></li><li><a href=\"#H1989275014\" id=\"outline-link-H1989275014\">Non-obstructive symptoms</a><ul><li><a href=\"#H1586262917\" id=\"outline-link-H1586262917\">- Initial treatment</a></li><li><a href=\"#H2733343658\" id=\"outline-link-H2733343658\">- Monitoring response to treatment</a></li><li><a href=\"#H1506324249\" id=\"outline-link-H1506324249\">- Duration of therapy in responders</a></li><li><a href=\"#H1662276371\" id=\"outline-link-H1662276371\">- Alternative approaches and refractory disease</a></li></ul></li></ul></li><li><a href=\"#H22\" id=\"outline-link-H22\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/2602|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=GAST/115883\" class=\"graphic graphic_algorithm\">- Management of sclerosing mesenteritis</a></li></ul></li><li><div id=\"GAST/2602|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/114835\" class=\"graphic graphic_diagnosticimage\">- Fat ring and pseudocapsule in sclerosing mesenteritis</a></li></ul></li><li><div id=\"GAST/2602|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/64321\" class=\"graphic graphic_table\">- Mesenteric disease terms</a></li><li><a href=\"image.htm?imageKey=GAST/81532\" class=\"graphic graphic_table\">- Diff dx mesenteric masses</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=6-mercaptopurine-6-mp-metabolite-monitoring-and-tpmt-testing-in-patients-with-inflammatory-bowel-disease\" class=\"medical medical_review\">6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in patients with inflammatory bowel disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-of-abdominal-pain-in-adults\" class=\"medical medical_review\">Causes of abdominal pain in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chronic-mesenteric-ischemia\" class=\"medical medical_review\">Chronic mesenteric ischemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of familial adenomatous polyposis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-urinary-tract-obstruction-and-hydronephrosis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of urinary tract obstruction and hydronephrosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-primary-gastrointestinal-lymphomas\" class=\"medical medical_review\">Clinical presentation and diagnosis of primary gastrointestinal lymphomas</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=desmoid-tumors-epidemiology-risk-factors-molecular-pathogenesis-clinical-presentation-diagnosis-and-local-therapy\" class=\"medical medical_review\">Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-the-carcinoid-syndrome-and-tumor-localization\" class=\"medical medical_review\">Diagnosis of the carcinoid syndrome and tumor localization</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-classification-clinical-presentation-prognostic-features-and-diagnostic-work-up-of-gastrointestinal-stromal-tumors-gist\" class=\"medical medical_review\">Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal stromal tumors (GIST)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-features-and-diagnosis-of-mechanical-small-bowel-obstruction-in-adults\" class=\"medical medical_review\">Epidemiology, clinical features, and diagnosis of mechanical small bowel obstruction in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-adults-with-ascites\" class=\"medical medical_review\">Evaluation of adults with ascites</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=general-toxicity-of-cyclophosphamide-in-rheumatic-diseases\" class=\"medical medical_review\">General toxicity of cyclophosphamide in rheumatic diseases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=malignancy-related-ascites\" class=\"medical medical_review\">Malignancy-related ascites</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=managing-the-side-effects-of-tamoxifen\" class=\"medical medical_review\">Managing the side effects of tamoxifen</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-management-of-mechanical-small-bowel-obstruction-in-adults\" class=\"medical medical_review\">Overview of management of mechanical small bowel obstruction in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-mechanical-colorectal-obstruction\" class=\"medical medical_review\">Overview of mechanical colorectal obstruction</a></li></ul></div></div>","javascript":null}